TC for Breast Cancer — Docetaxel and Cyclophosphamide

TC uses docetaxel and cyclophosphamide only, with no anthracycline. AC-T uses doxorubicin and cyclophosphamide first, followed by a taxane — usually paclitaxel or docetaxel — in a second phase. The key distinction is that TC contains no anthracycline. Anthracyclines carry a small risk of cardiac toxicity with cumulative exposure, which is why TC is preferred when a patient already has heart disease or other cardiac risk factors. Both are listed in NCCN guidelines as options for early breast cancer.

A typical course involves four to six cycles, each spaced three weeks apart. The exact number is decided by your oncologist before treatment starts, based on your stage, tumour characteristics, and how you tolerate the regimen. The plan may be reviewed during treatment if side effects require it, but the decision to change the number of cycles always rests with your treating team.

Hair loss is a common side effect of docetaxel and is expected in most people receiving TC. It usually begins within the first few weeks of starting treatment. Hair typically starts to return after your last cycle, though the timeline varies between individuals. Some people also experience nail changes — discolouration, brittleness or separation — during treatment. Both are worth mentioning to your team so they can advise on care.

Anthracyclines such as doxorubicin can reduce heart muscle function with cumulative doses over time. The risk is small in otherwise healthy people, but it becomes clinically significant if you have pre-existing heart disease, reduced cardiac function, uncontrolled high blood pressure, or other cardiac risk factors. When those risks are present, an anthracycline-free regimen that still addresses the cancer becomes the more appropriate choice. Your oncologist will have reviewed your cardiac history before recommending TC.

Give your oncologist and pharmacist a complete list of every medicine you take, including over-the-counter drugs, supplements, and herbal products. Some medicines interact with docetaxel or cyclophosphamide because they are processed by the same liver pathways. Your oncologist will review the list and advise on any that need to be adjusted or paused. Do not stop or change any prescription medicine without that review.

Call your oncology team the same day — or go to the emergency department if you cannot reach them — if you develop a fever, feel unusually unwell, notice rapid or worsening swelling, cannot keep fluids down, or develop chest pain or shortness of breath. Low white cell count after chemotherapy can make an ordinary infection dangerous even when it starts mildly. Do not wait for your next scheduled appointment if you are uncertain.